Skip to main content
Gut logoLink to Gut
. 2001 Jul;49(1):152–153. doi: 10.1136/gut.49.1.152

Recurrent Clostridium difficile diarrhoea

L Kyne 1, C Kelly 1
PMCID: PMC1728368  PMID: 11413124

Full Text

The Full Text of this article is available as a PDF (80.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Buggy B. P., Fekety R., Silva J., Jr Therapy of relapsing Clostridium difficile-associated diarrhea and colitis with the combination of vancomycin and rifampin. J Clin Gastroenterol. 1987 Apr;9(2):155–159. doi: 10.1097/00004836-198704000-00009. [DOI] [PubMed] [Google Scholar]
  2. Fekety R. Guidelines for the diagnosis and management of Clostridium difficile-associated diarrhea and colitis. American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 1997 May;92(5):739–750. [PubMed] [Google Scholar]
  3. Kelly C. P., Pothoulakis C., LaMont J. T. Clostridium difficile colitis. N Engl J Med. 1994 Jan 27;330(4):257–262. doi: 10.1056/NEJM199401273300406. [DOI] [PubMed] [Google Scholar]
  4. Kyne L., Kelly C. P. Prospects for a vaccine for Clostridium difficile. BioDrugs. 1998 Sep;10(3):173–181. doi: 10.2165/00063030-199810030-00001. [DOI] [PubMed] [Google Scholar]
  5. Kyne L., Warny M., Qamar A., Kelly C. P. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet. 2001 Jan 20;357(9251):189–193. doi: 10.1016/S0140-6736(00)03592-3. [DOI] [PubMed] [Google Scholar]
  6. Kyne L., Warny M., Qamar A., Kelly C. P. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med. 2000 Feb 10;342(6):390–397. doi: 10.1056/NEJM200002103420604. [DOI] [PubMed] [Google Scholar]
  7. Leung D. Y., Kelly C. P., Boguniewicz M., Pothoulakis C., LaMont J. T., Flores A. Treatment with intravenously administered gamma globulin of chronic relapsing colitis induced by Clostridium difficile toxin. J Pediatr. 1991 Apr;118(4 Pt 1):633–637. doi: 10.1016/s0022-3476(05)83393-1. [DOI] [PubMed] [Google Scholar]
  8. McFarland L. V., Surawicz C. M., Greenberg R. N., Fekety R., Elmer G. W., Moyer K. A., Melcher S. A., Bowen K. E., Cox J. L., Noorani Z. A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA. 1994 Jun 22;271(24):1913–1918. [PubMed] [Google Scholar]
  9. Olson M. M., Shanholtzer C. J., Lee J. T., Jr, Gerding D. N. Ten years of prospective Clostridium difficile-associated disease surveillance and treatment at the Minneapolis VA Medical Center, 1982-1991. Infect Control Hosp Epidemiol. 1994 Jun;15(6):371–381. doi: 10.1086/646934. [DOI] [PubMed] [Google Scholar]
  10. Tedesco F. J., Gordon D., Fortson W. C. Approach to patients with multiple relapses of antibiotic-associated pseudomembranous colitis. Am J Gastroenterol. 1985 Nov;80(11):867–868. [PubMed] [Google Scholar]

Articles from Gut are provided here courtesy of BMJ Publishing Group

RESOURCES